Bubu A Banini1,2, Divya P Kumar1,3, Hae-Ki Min1, Arun J Sanyal1, Sophie Cazanave1,4, Mulugeta Seneshaw1, Faridoddin Mirshahi1, Prasanna K Santhekadur3, Liangsu Wang5, Hong Ping Guan5, Abdul M Oseini1, Cristina Alonso6, Pierre Bedossa7, Srinivas V Koduru8,9. 1. Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA. 2. Section of Digestive Diseases, Yale University, New Haven, CT. 3. Department of Biochemistry, CEMR, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, Karnataka, India. 4. Glympse Bio, Cambridge, MA. 5. Merck & Co., Inc., Kenilworth, NJ. 6. OWL Metabolomics, Technology Park of Bizkaia, Derio, Bizkaia, Spain. 7. Department of Pathology, Physiology, and Imaging, University Paris Diderot, Paris, France. 8. Gene Arrays, Entity of Vedic Research, New York, NY. 9. Department of Surgery, Penn State College of Medicine, Hershey, PA.
Abstract
BACKGROUND AND AIMS: The mechanisms by which the I148M mutant variant of the patatin-like phospholipase domain-containing 3 (PNPLA3I148M ) drives development of nonalcoholic steatohepatitis (NASH) are not known. The aim of this study was to obtain insights on mechanisms underlying PNPLA3I148M -induced acceleration of NASH. APPROACH AND RESULTS: Hepatocyte-specific overexpression of empty vector (luciferase), human wild-type PNPLA3, or PNPLA3I148M was achieved using adeno-associated virus 8 in a diet-induced mouse model of nonalcoholic fatty liver disease followed by chow diet or high-fat Western diet with ad libitum administration of sugar in drinking water (WDSW) for 8 weeks. Under WDSW, PNPLA3I148M overexpression accelerated steatohepatitis with increased steatosis, inflammation ballooning, and fibrosis (P < 0.001 versus other groups for all). Silencing PNPLA3I148M after its initial overexpression abrogated these findings. PNPLA3I148M caused 22:6n3 docosahexanoic acid depletion and increased ceramides under WDSW in addition to increasing triglycerides and diglycerides, especially enriched with unsaturated fatty acids. It also increased oxidative stress and endoplasmic reticulum stress. Increased total ceramides was associated with signature of transducer and activator of transcription 3 (STAT3) activation with downstream activation of multiple immune-inflammatory pathways at a transcriptomic level by network analyses. Silencing PNPLA3I148M reversed STAT3 activation. Conditioned media from HepG2 cells overexpressing PNPLA3I148M increased procollagen mRNA expression in LX2 cells; this was abrogated by hepatocyte STAT3 inhibition. CONCLUSIONS: Under WDSW, PNPLA3I148M overexpression promotes steatosis and NASH by metabolic reprogramming characterized by increased triglycerides and diglycerides, n3 polyunsaturated fatty acid depletion, and increased ceramides with resultant STAT3 phosphorylation and downstream inflammatory pathway activation driving increased stellate cell fibrogenic activity.
BACKGROUND AND AIMS: The mechanisms by which the I148M mutant variant of the patatin-like phospholipase domain-containing 3 (PNPLA3I148M ) drives development of nonalcoholic steatohepatitis (NASH) are not known. The aim of this study was to obtain insights on mechanisms underlying PNPLA3I148M -induced acceleration of NASH. APPROACH AND RESULTS: Hepatocyte-specific overexpression of empty vector (luciferase), human wild-type PNPLA3, or PNPLA3I148M was achieved using adeno-associated virus 8 in a diet-induced mouse model of nonalcoholic fatty liver disease followed by chow diet or high-fat Western diet with ad libitum administration of sugar in drinking water (WDSW) for 8 weeks. Under WDSW, PNPLA3I148M overexpression accelerated steatohepatitis with increased steatosis, inflammation ballooning, and fibrosis (P < 0.001 versus other groups for all). Silencing PNPLA3I148M after its initial overexpression abrogated these findings. PNPLA3I148M caused 22:6n3 docosahexanoic acid depletion and increased ceramides under WDSW in addition to increasing triglycerides and diglycerides, especially enriched with unsaturated fatty acids. It also increased oxidative stress and endoplasmic reticulum stress. Increased total ceramides was associated with signature of transducer and activator of transcription 3 (STAT3) activation with downstream activation of multiple immune-inflammatory pathways at a transcriptomic level by network analyses. Silencing PNPLA3I148M reversed STAT3 activation. Conditioned media from HepG2 cells overexpressing PNPLA3I148M increased procollagen mRNA expression in LX2 cells; this was abrogated by hepatocyte STAT3 inhibition. CONCLUSIONS: Under WDSW, PNPLA3I148M overexpression promotes steatosis and NASH by metabolic reprogramming characterized by increased triglycerides and diglycerides, n3 polyunsaturated fatty acid depletion, and increased ceramides with resultant STAT3 phosphorylation and downstream inflammatory pathway activation driving increased stellate cell fibrogenic activity.
Authors: Elizabeth K Speliotes; Johannah L Butler; Cameron D Palmer; Benjamin F Voight; Joel N Hirschhorn Journal: Hepatology Date: 2010-09 Impact factor: 17.425
Authors: S C Cazanave; X Wang; H Zhou; M Rahmani; S Grant; D E Durrant; C D Klaassen; M Yamamoto; A J Sanyal Journal: Cell Death Differ Date: 2014-04-25 Impact factor: 15.828
Authors: Panu K Luukkonen; Auli Nick; Maarit Hölttä-Vuori; Christoph Thiele; Elina Isokuortti; Susanna Lallukka-Brück; You Zhou; Antti Hakkarainen; Nina Lundbom; Markku Peltonen; Marju Orho-Melander; Matej Orešič; Tuulia Hyötyläinen; Leanne Hodson; Elina Ikonen; Hannele Yki-Järvinen Journal: JCI Insight Date: 2019-08-22
Authors: Sophie Cazanave; Alexei Podtelezhnikov; Kristian Jensen; Mulugeta Seneshaw; Divya P Kumar; Hae-Ki Min; Prasanna K Santhekadur; Bubu Banini; Adolfo Gabriele Mauro; Abdul M Oseini; Robert Vincent; Keith Q Tanis; Andrea L Webber; Liangsu Wang; Pierre Bedossa; Faridoddin Mirshahi; Arun J Sanyal Journal: Sci Rep Date: 2017-12-08 Impact factor: 4.379
Authors: Daniel Lindén; Andrea Ahnmark; Piero Pingitore; Ester Ciociola; Ingela Ahlstedt; Anne-Christine Andréasson; Kavitha Sasidharan; Katja Madeyski-Bengtson; Magdalena Zurek; Rosellina M Mancina; Anna Lindblom; Mikael Bjursell; Gerhard Böttcher; Marcus Ståhlman; Mohammad Bohlooly-Y; William G Haynes; Björn Carlsson; Mark Graham; Richard Lee; Sue Murray; Luca Valenti; Sanjay Bhanot; Peter Åkerblad; Stefano Romeo Journal: Mol Metab Date: 2019-02-05 Impact factor: 7.422
Authors: Rocío Gallego-Durán; Rocío Montero-Vallejo; Douglas Maya-Miles; Ana Lucena; Franz Martin; Javier Ampuero; Manuel Romero-Gómez Journal: Front Immunol Date: 2021-11-24 Impact factor: 7.561
Authors: Ana Magdalena Velázquez; Roger Bentanachs; Aleix Sala-Vila; Iolanda Lázaro; Jose Rodríguez-Morató; Rosa María Sánchez; Juan Carlos Laguna; Núria Roglans; Marta Alegret Journal: Biomedicines Date: 2022-06-27
Authors: Elke Ericson; Linnéa Bergenholm; Anne-Christine Andréasson; Carly I Dix; Jane Knöchel; Sara F Hansson; Richard Lee; Jennifer Schumi; Madeleine Antonsson; Ola Fjellström; Patrik Nasr; Mathias Liljeblad; Björn Carlsson; Stergios Kechagias; Daniel Lindén; Mattias Ekstedt Journal: Hepatol Commun Date: 2022-07-14